ITOS iTeos Therapeutics Inc
Price (delayed)
$12.05
Market cap
$440.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3
Enterprise value
$194.2M
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of
Highlights
ITOS's equity is up by 23% from the previous quarter and by 6% YoY
The EPS is up by 21% since the previous quarter
The quick ratio is up by 39% QoQ but it is down by 12% YoY
ITOS's revenue has dropped by 59% year-on-year
iTeos Therapeutics's gross profit has plunged by 59% YoY
Key stats
What are the main financial stats of ITOS
Market
Valuations
Earnings
Shares outstanding
36.52M
Market cap
$440.09M
Enterprise value
$194.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.66
Price to sales (P/S)
13.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.55
Revenue
$35M
EBIT
-$102.48M
EBITDA
-$101.41M
Free cash flow
-$117.52M
Per share
Balance sheet
Liquidity
EPS
-$3
Free cash flow per share
-$2.96
Book value per share
$18.38
Revenue per share
$0.88
TBVPS
$18.94
Total assets
$751.84M
Total liabilities
$87.97M
Debt
$5.52M
Equity
$663.87M
Working capital
$591.94M
Debt to equity
0.01
Current ratio
18.08
Quick ratio
17.51
Net debt/EBITDA
2.42
Margins
Efficiency
Dividend
EBITDA margin
-289.8%
Gross margin
100%
Net margin
-309%
Operating margin
-413.8%
Return on assets
-15.9%
Return on equity
-18.2%
Return on invested capital
-23.3%
Return on capital employed
-14.3%
Return on sales
-292.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ITOS stock price
How has the iTeos Therapeutics stock price performed over time
Intraday
-27.84%
1 week
-22.56%
1 month
-19.34%
1 year
-2.19%
YTD
10.05%
QTD
-18.8%
Financial performance
How have iTeos Therapeutics's revenue and profit performed over time
Revenue
$35M
Gross profit
$35M
Operating income
-$144.82M
Net income
-$108.14M
Gross margin
100%
Net margin
-309%
The operating income has shrunk by 122% YoY but it rose by 16% QoQ
ITOS's revenue has dropped by 59% year-on-year
iTeos Therapeutics's gross profit has plunged by 59% YoY
The company's net income rose by 20% QoQ
Growth
What is iTeos Therapeutics's growth rate over time
Valuation
What is iTeos Therapeutics stock price valuation
P/E
N/A
P/B
0.66
P/S
13.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.55
The EPS is up by 21% since the previous quarter
ITOS's P/B is 49% below its 5-year quarterly average of 1.8 but 14% above its last 4 quarters average of 0.8
ITOS's equity is up by 23% from the previous quarter and by 6% YoY
ITOS's revenue has dropped by 59% year-on-year
Efficiency
How efficient is iTeos Therapeutics business performance
The ROIC has dropped by 188% year-on-year but it is up by 22% since the previous quarter
The ROE has grown by 21% from the previous quarter
The ROA has increased by 21% from the previous quarter
Dividends
What is ITOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ITOS.
Financial health
How did iTeos Therapeutics financials performed over time
The quick ratio is up by 39% QoQ but it is down by 12% YoY
The current ratio is up by 34% since the previous quarter but it has declined by 12% year-on-year
iTeos Therapeutics's debt is 99% lower than its equity
ITOS's equity is up by 23% from the previous quarter and by 6% YoY
iTeos Therapeutics's debt has decreased by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.